Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Grand Life Science Group (GLSG) is a leading Chinese pharmaceutical and healthcare conglomerate and a core division of China Grand Enterprises (CGE). The group operates a comprehensive industrial chain across five strategic sectors: blood products, vaccines, probiotics (live biotherapeutic products), medical nutrition, and perioperative medicines. Its flagship subsidiary, Grand Shuyang, is a global leader in the blood products industry, offering a portfolio that includes albumin, immunoglobulins, and coagulation factors. GLSG maintains a robust innovative pipeline of over 30 programs, highlighted by the Phase 3 anti-TFPI monoclonal antibody KN057 for hemophilia and a suite of Class-1 innovative vaccines. Through extensive R&D centers and high-standard manufacturing bases across China, the company integrates the entire value chain to provide advanced therapeutic solutions to patients worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Grand Life Science Group.